A preliminary phase 1 trial of AZD0780, the first oral small molecule PCSK9 inhibitor, has shown promising results in lowering LDL cholesterol levels. The study, presented at the European Atherosclerosis Society (EAS) 2024 conference, found that AZD0780 reduced LDL cholesterol by at least 30% in 35 participants with elevated LDL. A subanalysis within the trial suggested a potential synergistic effect when AZD0780 was combined with the statin rosuvastatin, resulting in a 78% reduction in LDL cholesterol levels. Rick Vega, Director of Research at AstraZeneca, stated that these findings indicate a fixed-dose combination of AZD0780 with a statin could be an attractive first-line treatment option.
Rosuvastatin lowers LDL slightly more than atorvastatin; LODESTAR outcomes were similar
Comparison of the two high-intensity statins: both lower LDL-C by 50% or more, rosuvastatin is more potent per milligram, but in the randomized LODESTAR trial 3-year clinical outcomes did not differ significantly. The goal is reaching the appropriate LDL target on maximally tolerated therapy.



